| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510942 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905713 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10918662 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11684636 | EXELA PHARMA | Stable, highly pure l-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11826383 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10905714 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10933089 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10912795 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11679125 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11642370 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11510941 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US11648262 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
Elcys is owned by Exela Pharma.
Elcys contains Cysteine Hydrochloride.
Elcys has a total of 15 drug patents out of which 0 drug patents have expired.
Elcys was authorised for market use on 16 April, 2019.
Elcys is available in solution;intravenous dosage forms.
Elcys can be used as method of using l-cysteine in an admixture for treating patients needing parenteral nutrition.
The generics of Elcys are possible to be released after 15 January, 2039.
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
ELCYS family patents
